MediciNova Completes Enrollment for Phase 2 Trial of MN-166 in Metastatic Colorectal Cancer
I'm PortAI, I can summarize articles.
MediciNova, Inc. has completed patient enrollment for its Phase 2 OXTOX study, evaluating MN-166 for preventing chemotherapy-induced peripheral neuropathy in metastatic colorectal cancer patients. The trial, led by Dr. Janette Vardy and Dr. Haryana Dhillon, involved 100 patients across 11 sites in Australia. Results are pending. This information was published by MediciNova via GlobeNewswire on December 18, 2025.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments